Neurogene Inc. (NASDAQ: NGNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
Meridian Small Cap Growth Fund Trimmed Neurogene (NGNE) on Share Price Appreciation [Yahoo! Finance]
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome [Yahoo! Finance]
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
Neurogene Inc. (NASDAQ: NGNE) was upgraded by analysts at Baird R W to a "strong-buy" rating.